TIGIT and neoplasm: Treatment with anti-PD-L1 + mIgG2a anti-TIGIT antibodies increased the proportion of gp70-specific CD8+ T cells in the tumour (Fig. 5d) and drove those cells to downregulate TOX while upregulating TCF1, consistent with a shift from exhausted effector cells towards a more memory-like state (Fig. 5e,f).